
Press Release

October 30, 2024

Sumitomo Pharma Co., Ltd.

Sumitomo Pharma Announces Organizational Realignment and Changes in Executive Officers and Other Key Positions

Sumitomo Pharma Co., Ltd. (Head Office: Osaka, Japan; Representative Director, President and CEO: Toru Kimura) today announced the following organizational realignment and changes in Executive Officers and other key positions, effective December 1, 2024, as part of fundamental business structural reform.

I. Organizational Realignment (effective December 1, 2024)

Corporate Departments

Related functional departments are integrated and reorganized into a lean and efficient organization.

1. Part of function of Global Corporate Strategy is transferred to newly created R&D Strategy and Planning under Research and Development Division.
2. IT Management & Data Analytics is created by integrating Global Data Design Office and IT Management & Digital Transformation.
3. Regulatory Affairs is transferred to under Corporate Regulatory Compliance & Quality Assurance Division.
4. Corporate Secretariat is dissolved and its functions are transferred to External Affairs.
5. Part of function of Corporate Governance is transferred to Legal Affairs and Legal Affairs is renamed to Legal & Compliance.
6. Corporate Communications is dissolved and its functions are transferred to Global Finance and Corporate Governance.
7. Medical Science is dissolved and its functions are transferred to Regulatory Affairs under Corporate Regulatory Compliance & Quality Assurance Division and newly created Medical Affairs under Research and Development Division.

Corporate Regulatory Compliance & Quality Assurance (Division)

Regulatory Compliance & Quality Assurance Management is renamed (in Japanese language only).

Research and Development (Division) (Currently, Drug Research Division, Drug Development Division, and Technology Research & Development Division)

Drug Research Division, Drug Development Division, and Technology Research & Development Division are integrated and reorganized into a lean organization to promote R&D activities under a unified activity strategy.

1. Research and Development Division is created by integrating Drug Research Division, Drug

- Development Division, and Technology Research & Development Division.
2. R&D Strategy and Planning is created by integrating part of function of Research Planning & Coordination, Development Planning & Management, and Technology Research & Development Management, and External Innovation.
 3. R&D Management is created by integrating part of function of Research Planning & Coordination, Development Planning & Management, and Technology Research & Development Management.
 4. CNS Drug Discovery Research Unit is created by integrating part of function of Pharmacology Research Unit and Platform Technology Research Unit.
 5. Modality Research Unit is dissolved and its functions are transferred to Cancer Drug Discovery Research Unit.
 6. Drug Discovery Digital Innovation Unit is created by integrating part of function of Research Planning & Coordination, Platform Technology Research Unit, and Technology Research & Development Management.
 7. Part of function of Development Planning & Management is transferred to Clinical Operation.
 8. Process Research & Development Laboratories is renamed to Process R&D Unit.
 9. Formulation Research & Development Laboratories is renamed to Formulation R&D Unit.
 10. Analytical Research & Development Laboratories is renamed to Analytical R&D Unit.
 11. Medical Affairs is created.

Research Planning & Coordination, Development Planning & Management, Technology Research & Development Management, and Platform Technology Research Unit are dissolved by integrating and transferring their functions to newly created departments.

Sales & Marketing (Division)

Division's functions and branches are integrated for efficient organization and productivity improvement.

1. MarTech Strategy Office and Personnel Development are dissolved and their functions are transferred to Sales & Marketing Management.
2. Product Marketing is created by integrating part of function of Sales & Marketing Management and Rare Diseases Office, Product Marketing, and CNS Product Marketing.
3. Distribution Management is renamed to Distribution Policy Management.
4. Hokkaido-Tohoku Branch is created by integrating Sapporo Branch and Tohoku Branch.
5. Kanto-Koshinetsu Branch is created by integrating Kita-Kanto-Koshinetsu Branch and part of Saitama-Chiba Branch.
6. Shutoken Branch is created by integrating part of Saitama-Chiba Branch, Tokyo Branch, and Yokohama Branch.
7. Tokai-Hokuriku Branch is created by integrating Tokai Branch and part of Keiji-Hokuriku Branch.
8. Kansai Branch is created by integrating by part of Keiji-Hokuriku Branch and Osaka Branch.
9. Chugoku-Shikoku Branch is created by integrating Chugoku Branch and Shikoku Branch.

Supply Chain (Division)

1. Manufacturing Division is renamed to Supply Chain Division.
2. Manufacturing Management is renamed to Supply Chain Management.

II. Changes in Executive Officers

(1) Promotion (effective December 1, 2024)

Managing Executive Officer

Yumi Sato (currently Executive Officer)

(2) New Executive Officers (effective December 1, 2024)

Koji Yamazaki (currently Sales & Marketing Division, Senior Vice President, Head of Sales & Marketing Division)

Kimihiro Mizuno (currently Senior Vice President, Head of Manufacturing Division)

(3) Departing Executive Officers (effective November 30, 2024)

Yoshiharu Ikeda (currently Managing Executive Officer)

Hiroyuki Baba (currently Managing Executive Officer)

Naoki Noguchi (currently Executive Officer)

(4) Changes in the Positions Assumed by Executive Officers (effective December 1, 2024)

Position as of December 1, 2024	Current position	Name
Representative Director, Executive Vice President Global Corporate Strategy; Global Finance; Legal & Compliance; Intellectual Property; Human Resources; External Affairs; Corporate Governance; IT Management & Data Analytics Administration	Representative Director, Executive Vice President Global Corporate Strategy; Corporate Governance; Human Resources; Global Finance Administration	Motoyuki Sakai
Member, Board of Directors, Executive Officer President and CEO, Sumitomo Pharma America, Inc. North America Business	Member, Board of Directors, Executive Officer President and CEO, Sumitomo Pharma America, Inc.	Tsutomu Nakagawa
Managing Executive Officer Business Development & Management	Managing Executive Officer Business Development & Management Vice President, Head of Business Development & Management	Shigeyuki Nishinaka

Vice President, Head of Business Development & Management Asia Business		
Managing Executive Officer Supply Chain Division Senior Vice President, Head of Supply Chain Division Head of Japan Business Unit	Managing Executive Officer Technology Research & Development Division; Manufacturing Division Deputy Head of Japan Business Unit	Hideyuki Harada
Managing Executive Officer Legal & Compliance; Intellectual Property; Human Resources; External Affairs; Corporate Governance; IT Management & Data Analytics	Managing Executive Officer External Affairs; Corporate Secretariat; Human Resources	Atsuko Higuchi
Managing Executive Officer Research and Development Division Senior Vice President, Head of Research and Development Division Chief Development Officer, Sumitomo Pharma America, Inc.	Executive Officer Drug Development Division Senior Vice President, Head of Drug Development Division Chief Development Officer, Sumitomo Pharma America, Inc.	Yumi Sato
Executive Officer Corporate Regulatory Compliance & Quality Assurance Division Senior Vice President, Head of Corporate Regulatory Compliance & Quality Assurance Division Deputy Head of Japan Business Unit	Executive Officer Regulatory Affairs; Medical Science; Corporate Regulatory Compliance & Quality Assurance Senior Vice President, Head of Corporate Regulatory Compliance & Quality Assurance Division Deputy Head of Japan Business Unit	Koichi Kozuki
Executive Officer Senior Vice President, Deputy Head of Research and Development Division (Drug Discovery Research)	Executive Officer Senior Vice President, Head of Drug Research Division Senior Executive Research Director	Isao Shimizu
Executive Officer Senior Vice President, Deputy Head of Research and Development Division (CMC)	Executive Officer Senior Vice President, Head of Technology Research & Development Division	Kenji Ueno
Executive Officer Sales & Marketing Division Senior Vice President, Head of Sales & Marketing Division Deputy Head of Japan Business Unit	Sales & Marketing Division Senior Vice President, Head of Sales & Marketing Division Deputy Head of Japan Business Unit	Koji Yamazaki

Executive Officer Legal & Compliance; Intellectual Property; Human Resources	Senior Vice President, Head of Manufacturing Division Deputy Head of Japan Business Unit	Kimihiro Mizuno
--	--	--------------------

III. Changes in Personnel (effective December 1, 2024)

Corporate Departments

Position as of December 1, 2024	Current position	Name
Regenerative & Cellular Medicine Office; Regenerative & Cellular Medicine Kobe Center; Regenerative & Cellular Medicine Manufacturing Plant; External Affairs; Corporate Governance; IT Management & Data Analytics Vice President, Head of External Affairs Vice President, Head of Regenerative & Cellular Medicine Office	Regenerative & Cellular Medicine Office; Regenerative & Cellular Medicine Kobe Center; Regenerative & Cellular Medicine Manufacturing Plant Vice President, Head of Regenerative & Cellular Medicine Office	Tomokazu Nagano
Vice President, Head of Legal & Compliance	Senior Director, Group I, Legal Affairs	Kazuhisa Kitazawa
Vice President, Head of Intellectual Property	Senior Director, Group II, Intellectual Property	Kazuo Eiho
Vice President, Head of Human Resources	Vice President, Head of Personnel Development	Tomoko Nakagawa
Vice President, Head of IT Management & Data Analytics	Vice President, Head of Global Data Design Office	Satoru Tsuchiya

Corporate Regulatory Compliance & Quality Assurance (Division)

Position as of December 1, 2024	Current position	Name
Vice President, Head of Regulatory Compliance & Quality Assurance Management (in Japanese language only)	Vice President, Head of Regulatory Compliance & Quality Assurance Management	Kaori Kato
Vice President, Head of Quality Management	Vice President, Head of Oita Plant	Toyohiro Nishikawa

Research and Development (Division)

Position as of December 1, 2024	Current position	Name
Senior Vice President, Deputy Head of Research and Development Division (Project Planning and Promotion)	Senior Research Project Director, Late-phase Drug Research	Taro Kato
Vice President, Project Director, CNS Drug Discovery	Vice President, Head of, Pharmacology Research Unit Senior Director, Pharmacology Group IV, Pharmacology Research Unit	Mitsugu Yamanaka
Vice President, CMC Program Director	Senior Director, CMC Planning & Management Group, Technology Research & Development Management	Shohei Horiuchi
Vice President, Head of R&D Strategy and Planning	Vice President, Head of Research Planning & Coordination Senior Director, Research Intelligence Group, Research Planning & Coordination	Masakuni Horiguchi
Vice President, Head of R&D Management	Vice President, Head of Development Planning & Management Senior Director, Program Management Group, Development Planning & Management	Katsunori Maruta
Vice President, Head of CNS Drug Discovery Research Unit	Executive Research Director, Drug Research Division	Takeo Ishiyama
Vice President, Head of Cancer Drug Discovery Research Unit	Vice President, Head of Modality Research Unit Vice President, Head of Cancer Research Unit	Hitoshi Ban
Vice President, Head of Chemistry Research Unit	Vice President, Head of Chemistry Research Unit Senior Director, Medicinal Chemistry Group II, Chemistry Research Unit	Katsunori Tsuboi
Vice President, Head of Preclinical Research Unit	Vice President, Head of Preclinical Research Unit Senior Director, Toxicology Group II, Preclinical Research Unit	Izuru Miyawaki
Vice President, Head of Drug Discovery Digital Innovation Unit	Senior Research Project Director, Early-phase Drug Research	Hidetaka Nagata

Vice President, Head of Process R&D Unit	Vice President, Head of Process Research & Development Laboratories Senior Director, New Modality Group, Process Research & Development Laboratories	Nobuhisa Fukuda
Vice President, Head of Formulation R&D Unit	Vice President, Head of Formulation Research & Development Laboratories	Makiko Yanagida
Vice President, Head of Analytical R&D Unit	Senior Director, Drug Development Analytical Research Group, Analytical Research & Development Laboratories	Yoshiaki Takai
Vice President, Head of Medical Affairs	Vice President, Head of Medical Science	Keiko Hirano

Sales & Marketing (Division)

Position as of December 1, 2024	Current position	Name
Vice President, Head of Sales & Marketing Management	Vice President, Head of Yokohama Branch	Yasuhiro Kami
Vice President, Head of Product Marketing	Vice President, Head of Sales & Marketing Management	Yasutoshi Araki
Vice President, Head of Distribution Policy Management	Vice President, Head of Distribution Management	Manabu Tatsukawa
Vice President, Head of Hokkaido-Tohoku Branch	Vice President, Head of Sapporo Branch Senior Director, Wholesaler Service Group, Sapporo Branch	Toshinori Kanata
Vice President, Head of Kanto-Koshinetsu Branch	Vice President, Head of Kita-Kanto-Koshinetsu Branch	Hiroshi Ogawa
Vice President, Head of Shutoken Branch	Vice President, Head of Tokyo Branch	Katsuhiko Nishida
Vice President, Head of Tokai-Hokuriku Branch	Vice President, Head of Tokai Branch Senior Director, Wholesaler Service Group, Tokai Branch	Satsuki Otani
Vice President, Head of Kansai Branch	Vice President, Head of Product Marketing	Yoshihiro Ariyama
Vice President, Head of Chugoku-Shikoku Branch	Vice President, Head of CNS Product Marketing	Masashi Kimura

	Senior Director, CNS Product Group II, CNS Product Marketing	
--	---	--

Supply Chain (Division)

Position as of December 1, 2024	Current position	Name
Vice President, Head of Supply Chain Management Senior Director, Strategic Supply Chain Planning Group, Supply Chain Management	Vice President, Head of Administration, Suzuka Plant	Tetsuya Yamaji
Vice President, Head of Manufacturing Technology	Senior Director, Formulation Technology Group, Manufacturing Technology	Takayuki Murakami
Vice President, Head of Suzuka Plant	Vice President, Head of Manufacturing Technology Senior Director, Packaging Technology Group, Manufacturing Technology	Takahiro Jikihara
Vice President, Head of Administration, Suzuka Plant	Senior Director, Procurement Management Group, Manufacturing Management	Hirokuni Nakanishi
Vice President, Head of Manufacturing Department, Suzuka Plant	Vice President, Head of Manufacturing Department I, Suzuka Plant	Satoshi Nakao
Vice President, Head of Engineering, Suzuka Plant Senior Director, Maintenance Group, Engineering, Suzuka Plant	Senior Director, Maintenance Group, Engineering, Suzuka Plant	Junichi Muto
Vice President, Head of Oita Plant	Vice President, Head of Quality Assurance, Oita Plant Senior Director, Quality Assurance Group, Quality Assurance, Oita Plant	Toshiyuki Hosokawa
Vice President, Head of Quality Assurance, Oita Plant Senior Director, Quality Assurance Group, Quality Assurance, Oita Plant	Senior Director, Quality Assurance Group II, Quality Management	Yasuo Takizawa

Contact:

Corporate Communications

Sumitomo Pharma Co., Ltd.

E-mail: prir@sumitomo-pharma.co.jp